Início > > Resultado da busca

Resultados: 2

Primary results from post hoc analysis of the apollo-b brazilian subpopulation, a phase 3 study of patisiran in patients with transthyretin amyloidosis with cardiomyopathy

Mesquita, Cláudio Tinoco; Schwartzmann, Pedro V; Correia, Edileide de Barros; Simões, Marcus Vinicius; Biolo, Andréia; Duque, Daniel Rodriguez; Jay, Patrick Y; Fernandes, Fabio.
Arq. bras. cardiol; 121 (9 supl.1), 2024
BACKGROUND: Transthyretin amyloidosis (ATTR) is a progressive, fatal disease caused by toxic misfolded transthyretin (TTR) amyloid deposits. Patisiran, an RNA interference therapeutic, inhibits synthesis of wild-type and variant TTR and is approved for the treatment of hereditary ATTR with polyneuropathy...
^dd0000708570, ^dd0117880, ^dd0112280, ^dd0582250, ^dd0006860, ^dd0154150, ^dd0092020, ^dd0118770
Texto completo

APOLLO-B, a study of patisiran in patients with transthyretin cardiac amyloidosis: primary long-term results from the open-label extension period

Hung, Rebecca R; Correia, Edileide de Barros; Berk, John L; Drachman, Brian; Fontana, Marianna; Gillmore, Julian D; Mesquita, Claudio T; Simoes, Marcus V; Yureneva, Elena; White, Matthew T; Sweetser, Marianne T; Jay, Patrick Y; Vest, John; Maurer, Mathew S.
Circulation; 148 (Suppl.1), 2023
INTRODUCTION: The Phase 3 APOLLO-B study evaluates patisiran in patients (pts) with transthyretin (ATTR) cardiac amyloidosis over a 12-month (M) double-blind (DB) period, followed by an open-label extension (OLE) period when all pts receive patisiran (NCT03997383). Hypothesis: Patisiran provides long-ter...
^dd0006860, ^dd0063330, ^dd0043640, ^dd0112280, ^dd0117880, ^dd0138120, ^dd0192100
Texto completo